Roman Tremmel

Latest

Pharmacogenetic Implementation Studies-Lessons Learned From the PREPARE Study.
Machine learning models for pharmacogenomic variant effect predictions - recent developments and future frontiers.
Comprehensive analysis of multi-omics single-cell data using the single-cell analyst.
The liver proteome of individuals with a natural UGT2B17 complete deficiency.
PharmFreq: a comprehensive atlas of ethnogeographic allelic variation in clinically important pharmacogenes.
Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes.
In silico and biological analyses of missense variants of the human biliary efflux transporter ABCC2: effects of novel rare missense variants.
Metabolic activation of WHO-congeners PCB28, 52, and 101 by human CYP2A6: evidence from in vitro and in vivo experiments.
A Semi-Mechanistic Population Pharmacokinetic Model of Noscapine in Healthy Subjects Considering Hepatic First-Pass Extraction and CYP2C9 Genotypes.
Genetic associations of cardiovascular risk genes in European patients with coronary artery spasm.
Single Cell Atlas: a single-cell multi-omics human cell encyclopedia.
Consequences of Amyloid-β Deficiency for the Liver.
Nutrimetric Validation of Solanidine as Dietary-Derived CYP2D6 Activity Marker In Vivo
Structural variation of the coding and non-coding human pharmacogenome
Translating pharmacogenomic sequencing data into drug response predictions-How to interpret variants of unknown significance
Circulating Biomarkers Instead of Genotyping to Establish Metabolizer Phenotypes
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
Cross-ancestry GWAS defines the extended CYP2D6 locus as the principal genetic determinant of endoxifen plasma concentrations
HTCA: a database with an in-depth characterization of the single-cell human transcriptome
Challenges and opportunities associated with rare-variant pharmacogenomics
Pharmacogenomics in pediatric medicine and drug development
Hepatic Expression of the Na+-Taurocholate Cotransporting Polypeptide Is Independent from Genetic Variation
Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving?
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets
How to manage polypharmacia?
Pharmacogenetic diagnostics to improve drug therapy in clinical practice
Antifibrotic Effects of Amyloid-Beta and Its Loss in Cirrhotic Liver.
α2-Adrenergic Receptor in Liver Fibrosis: Implications for the Adrenoblocker Mesedin.
Copy number variation profiling in pharmacogenes using panel-based exome resequencing and correlation to human liver expression.
The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center
A New Panel-Based Next-Generation Sequencing Method for ADME Genes Reveals Novel Associations of Common and Rare Variants With Expression in a Human Liver Cohort
Identification of Cardiomyopathy-Associated Circulating miRNA Biomarkers in Muscular Dystrophy Female Carriers Using a Complementary Cardiac Imaging and Plasma Profiling Approach
Influence of NOD2 Variants on Trichuris suis ova Treatment Outcome in Crohn’s Disease
Genetic variation in human drug-related genes.
Methyleugenol DNA adducts in human liver are associated with SULT1A1 copy number variations and expression levels.
Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.
Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma.